newsfilter
← Latest News
GlobeNewswire·

Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

  • Wolf Popper LLP is investigating potential claims for purchasers of Ionis Pharmaceuticals, Inc. (IONS) common stock.
  • The FDA approved Ionis' drug TRYNGOLZA in December 2024 for Familial Chylomicronemia Syndrome & in June 2026 for hypertriglyceridemia.
  • On November 9, 2026, Ionis reported third-quarter TRYNGOLZA sales of $9 million & lowered full-year guidance to $50 million from $100-$110 million.
  • Ionis stock fell 21.4% to $31.00 per share following the announcement of gradual sales performance & reduced guidance.
  • Investors wishing to discuss the investigation may contact Adam Savett at (212) 451-9655 or via email at asavett@wolfpopper.com.
Company
Wolf Popper LLP
Keywords
Wolf Popper LLP, CLASS ACTION LAWSUIT, LAW, securities, Class Action